On 21 March 2016, orphan designation (EU/3/16/1638) was granted by the European Commission to Eiger Biopharmaceuticals Europe Limited, United Kingdom, for ubenimex for the treatment of pulmonary arterial hypertension.
The sponsorship was transferred to Eigerbio Europe Limited, Ireland, in August 2019.
|Disease / condition||
Treatment of pulmonary arterial hypertension
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.